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B CELLS ARE the only eukaryotic cells that are able to
produce antibody molecules. Their growth and differ-
entiation into antibody producing cells require the presence
of T cells and macrophages; the function of these cells was
found to be replaced by soluble factors.￿3 In the early i980s
it was shown that at least two different kinds of factors were
required in the regulation of B cell response, one for growth
of activated B cells, B-cell growth factor (BCGF), and the
other for antibody induction in B cells, B-cell differentiation
factor (BCDF).￿6 Since then, a variety of factors regulating
the B cell response have been reported in the human and
murine systems. Finally, in 1986 the cDNAs for three B-cell
stimulatory factors have been cloned; interleukin-4 (IL-4)
(BCGF1 /BSF1 ) for the early activation of resting B cells,7’8
IL-5 (BCGFII) for the growth ofactivated B cells,9 and IL-6
(BCDF/BSF2) for the final differentiation of B cells into
antibody producing cells’#{176} (Fig 1).
Human IL-6 (BSF2) was originally identified as a factor
in the culture supernatants of mitogen or antigen-stimulated
peripheral mononuclear cells, which induced immunoglobu-
lin production in Epstein Barr virus (EBV) transformed
B-cell lines or in Staphylococcus aureus Cowan 1 (SAC)
stimulated normal B cells.t1 This molecule was found to be
separable from other factors, such as IL-2 and BCGFs, and
the establishment of human T cell hybridoma generating
BSF2 activity confirmed that this is a distinct molecule from
other cytokines.6 BSF2 was purified to homogeneity from
the culture supernatant of a human T-cell leukemia virus
type 1 (HTLV- 1) transformed T-cell line and its partial
N-terminal amino acid sequence was determined.t2 Based on
these findings, the cDNA encoding human BSF2 was
cloned. ￿#{176}
Approximately at the same time, the molecular cloning
and the nucleotide sequences of the molecules termed inter-
feron /￿2 (IFN￿32)’3 and 26 Kd protein were reportedt4 and the
results revealed that BSF2, IFN￿32, and 26 Kd protein were
identical. In I 980, an inducible mRNA species of about 13S
encoding for a novel human fibroblast-type interferon
(IFN), named 1FNf32 was reported.’5 The isolated cDNA
clone for such an induced mRNA was trancribed in vitro into
a protein of 26 Kd. One group detected an antiviral activity
that was neutralized with anti-IFNf￿2 and thus called this
molecule IFNj32)5 On the other hand, another group could
not detect any antiviral activity in this protein’6 and its
interferon activity was controversial until recombinant mole-
cules became available. In 1987 recombinant IL-6 (r IL-6)
was shown to have no IFN activity and to have antigenically
and functionally no relations with IFNfl.’7
Growth factors for plasmacytomas/myelomas have been
reported by several investigators.’8’20 In 1986, N-terminal
amino acid sequence of a human cytokine that showed
hybridoma/plasmacytoma growth factor activity was deter-
mined and the result again showed that the factor was
identical with BSF2/IFN/32/26 Kd protein.2’ Subsequently,
the cDNA cloning of murine hybridoma/plasmacytoma
growth factor was completed and the sequence indicated that
it was the murine homologue of IL-6/BSF2.2223 Therefore,
all the results demonstrated that IL-6 has the growth activity
in plasmacytoma/myeloma cells.
The other major activty of IL-6 is induction of acute phase
proteins in hepatocytes. The studies with IL-6 and anti-IL-6
antibody carried out by Gauldie et a124 and Andus et a125
clearly demonstrated that IL-6 functioned as a hepatocyte
stimulating factor (HSF) and induced the production of
major acute phase proteins.
As described, the molecular cloning of the cDNA of IL-6
indicated that the function of IL-6 is not restricted to B
lineage cells but shows a wide variety of biological activities
on various tissues and cells. Table 1 summarizes the activities
exerted by molecules identified to be identical to IL-6.
STRUCTURE OF IL-6
Human IL-6 consists of 184 amino acids with two poten-
tial N-glycosylation sites and four cysteine residues.1#{176}Com-
parison of the cDNA sequence of human IL-6 with that of
murine shows a homology of 65% at the DNA level and of
42% at the protein level.26 The position of four cysteine
residues is completely conserved and nine amino acid resi-
dues (no. 56 through 65) between two cysteine residues (no.
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Fig 1. Process of B-cell dif-
ferentiation and interleukins in-
volved in the process.
50 and 73) are identical, suggesting that the cysteine-rich
middle region of the mature protein may play a critical role
in IL-6 activity.2’ Recently, a biologically active recombinant
IL-6 gene was chemically synthesized on the basis of the
human IL-6 cDNA sequence.27 The result showed that a
cysteine-free, bioengineered rIL-6 protein was active, sug-
gesting that the primary sequence of IL-6 might contain the
information necessaary to fold the peptide chain into an
active conformation and cysteine residues might not be
required.
The sequence of IL-6 was compared with other known
proteins. Only G-CSF shows a significant homology with
IL-6’#{176}; the position of four cysteine residues of IL-6 match
with those of G-CSF. This suggests a similarity in the
tertiary structure of these two molecules and may indicate
some functional similarity as described later. Furthermore,
the gene organization of IL-6 shows a distinct similarity with
the G-CSF gene28; both genes have the same number of exons
and introns and the size of each exon is strikingly similar (Fig
2). Taken together, these findings suggest that the genes for
IL-6 and G-CSF might be evolutionarily derived from a
common ancestor gene.
REGULATION OF THE IL-6 EXPRESSION
IL-6 is produced by various types of lymphoid and non-
lymphoid cells, such as T cells, B cells, monocytes, fibro-
blasts, keratinocytes, endothelial cells, mesangium cells, and
several tumor cells, as summarized in Table 2. The produc-
tion of IL-6 by T cells requires the presence of monocytes,
while monocytes produced IL-6 in the absence of an appar-
ent stimulus in in vitro culture.29 The peak of IL-6 mRNA in
Table 1 . Molecules identical to 11-6
B-cell stimulatory factor 2
interferon f32
26 Kd protein
Myeloma/piasmacytoma growth factor
Hepatocyte stimulating factor
Macrophage granulocyte inducing factor 2
Cytotoxic T-cell differentiation factor
monocytes was achieved five hours following culture,
whereas that of T cells was at 24 to 48 hours after culture
initiation, suggesting that IL-6 produced by monocytes and
T cells with different kinetics may exert distinct effects, at
different phases of the immune responses.
The production of IL-6 in various cells is positively or
negatively regulated by a variety of signals. IL-6 production
in T cells is induced by T cell mitogens or antigenic stimula-
tion in the presence of direct contact with macrophages.￿
Lipopolysaccharide (LPS) enhances IL-6 production in
monocytes and fibroblasts.29’￿#{176} A variety of cytokines, includ-
ing IL-i, tumor necrosis factor (TNF), platelet-derived
growth factor (PDGF), and IFN/3 as well as serum,
poly(l)poly(C), and cycloheximide also enhance the expres-
sion of the IL-6 gene in different cell types.3’ Phorbol esters,
which activate protein kinase C,32 and agents that increase
intracellular cAMP33 also enhance the accumulation of IL-6
mRNA. Various viruses induce lL-6 production in fibro-
blasts￿’ or in the CNS.35 Human immunodelIciency virus
induces IL-6 production in monocytes.￿ Glucocorticoids
negatively regulate the IL-6 gene expression in various
tissues and cells.￿#{176}
The chromosomal DNA segments of human￿ and mouse￿
were isolated. The comparison revealed that the sequence
similarity in the coding region is about 60%, whereas the 3’
untranslated region and the first 300 bp sequence of the 5’
flanking region are highly conserved (-.90%), suggesting the
importance of the regulation of the IL-6 gene expression.
Sequences similar to transcriptional enhancer elements such
as the c-fos serum responsive element (SRE) and the consen-
sus sequences for cAMP induction (CRE), activator protein
I binding (AP-l) and the glucocorticoid receptor binding
(GRE) were identified within the highly conserved 5’-
flanking regions of the genes as shown in Fig 3.￿ These
sequences may play an important role in transcriptional
activation of the IL-6 gene.
Noteworthy is the striking similarity of transcriptional
regulation between the IL-6 and the c-fos genes. First, both
genes are induced rapidly without requirement of prior
protein synthesis. Second, a very broad range of stimuli
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modulate the gene expression in various tissues and cells.
These data suggest that both genes are likely to share some
cis-acting 5’ regulatory elements. In fact, the region involved
in IL-6 induction is mapped within the IL-6 promotor region
(- 180/ - 123 bp), which is homologous to c-fos SRE.
Nuclear factor(s) that recognize a 14 bp dyad symmetry
were identified within the c-fos SRE homology (Akira et al,
submitted). However, the dyad symmetry of the IL-6 promo-
tor is quite different from the dyad symmetry of the c-fos
promotor, suggesting that the nuclear factor(s) binding to
these dyad symmetries must be different from each other.
The transcriptional regulation of the IL-6 gene is quite
similar to that of the c-fos and these two genes have probably
developed to use the common modular structure in order to
respond to a variety of external stimuli common in the two
genes. However, the precise regulation is different and
specific between the two genes.
BIOLOGIC FUNCTION OF IL-6
Immune system. IL-6 was originally identified as T
cell-derived lymphokine that induces final maturation of B
cells into antibody producing cells)’￿2 The studies with the
IL-6 confirmed the activity of IL-6 on B cells. Thus, IL-6
could augment the production of 1gM, IgG, and IgA in
Pokeweed mitogen (PWM)-stimulated peripheral mononu-
clear cells (PBL) (Fig 4),37 IL-6 was also effective in in vivo
antibody production in mice primed to sheep RBCs
(SRBC).￿ As shown in Fig 4, the intraperitoneal administra-
tion of 10 ;zg rIL-6 every other day could augment anti-
SRBC secondary antibody response more than tenfold. The
study with anti-IL-6 antibody demonstrated that IL-6 is one
of the essential factors for antibody production in B cells;37
anti-IL-6 almost completely abrogated PWM-induced Ig-
production in PBL. However, mitogen-induced proliferation
of B cells was not affected at all by anti-IL-6 antibody,
indicating that IL-6 is not involved in the growth of activated
B cells. This shows a marked contrast to the fact that IL-6 is
a potent growth factor for myeloma/plasmacytoma cells as
described later.
Effect of IL-6 is not restricted to B cells, it can also act on
T cells. IL-6 receptors are expressed on activated but not
resting B cells, while resting T cells express IL-6 receptors,39
indicating that IL-6 acts only on the final maturation stage
of activated B cells, but can be effective on resting T cells. In
fact, IL-6 was shown to induce IL-2 roceptor￿#{176} as well as IL-2
production4’ in mitogen-stimulated T cells and thymocytes.
IL-6 promoted the growth of PHA-stimulated thymocytes
and peripheral T cells.42’￿’ The IL-6-induced growth of T
cells was found to be partly inhibited by anti-IL-2 or
anti-Tac antibody indicating that IL-6 can directly induce
the growth of T cells. The thymocyte costimulatory activity
of the macrophage- or T cell-derived conditioned medium
was largely abrogated by anti-IL-6 antibody.￿’ Previously, it
was thought that the thymocyte costimulatory activity was
exerted mainly by IL-i . However, the results obtained with
rIL-6 and anti-IL-6 antibody strongly suggest that IL-6 is an
Table 2. Producer Cells of lL-6
Normal tells Cell Lines Tumor Cells
T cells T-ceIl lines (HTLV-1 transformed) Cardiac myxoma cells
B cells
Monocytes
U937 .
(Monocyte cell lines)
P388D 1
Myeloma cells
Hypernephroma
Fibroblasts MG63 osteosarcoma cell line
Keratinocytes T24 bladder carcinoma line
Endothelial cells A549 lung carcinoma line
Astrocytes SK-MG-4 glioblastoma line
Bone marrow stroma cells U373 astrocytoma line
Mesangial cells
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essential accessory factor for T-cell activation and prolifera-
tion.
IL-6 induced not only proliferation but also the differen-
tiation of cytotoxic T cells (CTL) in the presence of IL-2
from murine as well as human thymocytes and splenic T
cells.47’￿ Previously, the requirement of a factor(s) other
than IL-2 for CTL induction was reported in various experi-
mental systems and they were called CDF, KHF, etc. The
result obtained with rIL-6 and anti-IL-6 has confirmed that
these factors are identical with IL-6. IL-6 induced serine
esterases required for the expression of cytotoxic function,
showing its critical role in cytotoxic T-cell differentiation.47
Hematopoiesis. The positive effect of IL-6 on hemato-
poiesis was first described by Ikebuchi et al.49 It was found
that IL-3 and IL-6 acted synergistically to support the
formation of multilineage blast cell colonies in murine spleen
cell cultures. The appearance of multilineage blast cell
colonies by IL-3 was significantly hastened by the addition of
IL-6, suggesting that IL-6 activate hematopoietic stem cells
at the G0 stage to enter into the G1 phase. Similar results
were observed by Koike et al.￿#{176} They showed that IL-6 and
IL-3 in serum free cultures increased multilineage blast cell
colonies but not single or oligolineage colonies, indicating
that IL-6 acts on the multipotent progenitors but not on the
more mature progenitors. Addition of IL-6 to cultures with a
low concentration of IL-3 resulted in a significant increase in
the number as well as the size of colonies, suggesting that the
other mechanism of synergism of IL-6 may be the enhance-
ment of the susceptibility of multipotent progenitors to IL-3,
possibly by upregulating IL-3 receptors.
Stanley et a15’ presented evidence that hematopoietin-l
(H-i), which was purified from culture supernatants of a
human bladder carcinoma cell line, 5637, possessed synergis-
tic activity with IL-3 in support of proliferation of hemato-
poietic progenitors. Recently, Mochizuki et al’2 and Moore
and Warren53 reported that IL-la and IL-ifl accounted for
the H-i activity of the 5637 supernatant. When highly
purified human marrow progenitors (Myl0￿ cells) were
used, IL-6 and IL-3 showed a synergy for the proliferation of
progenitors, while IL-la revealed no synergism with IL￿3.M
As bone marrow stroma cells produce large amounts of IL-6
following stimulation with IL-i, these results suggest an
indirect effect of IL-i in part mediated by IL-6.
The synergistic action of IL-6 with IL-3 for the prolifera-
tion of multiiineage progenitor cells suggests a potential role
for IL-6 in bone marrow transplantation. Short-term liquid
culture of murine nonadherent marrow cells with IL-6 and
IL-3 was found to increase the number of CFU-S approxi-
mately fivefold. When 2 x iO￿ nonadherent bone marrow
cells were transplanted to lethally irradiated recipients, the
survival rate at day 30 was only 20%. However, when these
cells were precultured with IL-6 plus IL-3 before transplan-
tation, the survival rate increased to 90% (Okana et al,
submitted). If this culture system is also efficient for expand-
ing human stem cells, it may be used in bone marrow
transplantation.
Human and murine myeloid leukemic cell lines, such as
human histiocytic U937 cells and mouse myeloid Mi cells
can be induced to differentiate into macrophages and granu-
locytes in vitro by several synthetic and natural products.
Several factors have been identified that can induce differen-
tiation of leukemic cells, such as G-CSF,55 MG1-2,56 and
leukemia inhibitory factor (LIF).57 Recently, IL-6 was also
shown to induce the differentiation of Ml cells into macro-
phages;58 IL-6 enhanced phagocytosis and expression of Fc￿y
and C3d receptors and its effect was much more potent than
that of vitamin D3.58 Sachs et al recently reported that
MGI-2 was identical with IL-6. LIF was also molecularly
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cloned and found to be a novel factor having no similarity
with either G-CSF or IL-6.57 However, noteworthy is that
LIF can induce a large amount of IL-6 in Mi cells. At
present, it is not known whether the effect of LIF on Ml cells
is direct or indirect through IL-6 production.
Acute phase reactions. The acute phase response is a
systemic reaction to inflammation or tissue injury. It is
characterized by leukocytosis, fever, increased vascular per-
meability, alterations in plasma metal and steroid concentra-
tion, along with increased levels of acute phase proteins. The
biosynthesis of acute phase proteins by hepatocytes is regu-
lated by several factors: IL-i, TNF, and HSF. IL-i was
originally considered to be the major acute phase regulator,
although it could only partially elicit the full acute phase
response. The studies with rIL-6 and anti-IL-6 antibody
demonstrated that IL-6 could function as HSF and the HSF
activity in monocyte conditioning medium was exerted by
IL-6 molecule.24’25 IL-6 could induce a variety ofacute phase
proteins, such as fibrinogen, alpha-l-antichymotrypsin,
alpha-i-acid glycoprotein, haptoglobin in human hepatoma
cell line, HepG2. In addition to those proteins, it induced
serum amyloid A, C-reactive protein, and alpha-i-antitryp-
sin in human primary hepatocytes.59 In vivo administration
of IL-6 in rats induced typical acute phase reactions similar
to that induced by the injection of turpentine. Moreover,
IL-6-induced expression of mRNAs for acute phase proteins
was more rapid than that induced by turpentine.￿#{176} The
results confirmed the in vivo role of IL-6 in acute phase
reaction. It was also reported that serum level of IL-6
correlated well with that of C-reactive protein and fever in
patients with severe burns, supporting the causal role of IL-6
in acute phase response.6’
Neural system. IL-i stimulation of glioblastoma cells or
astrocytoma cells was found to induce the expression of IL-6
mRNA, suggesting certain effects of IL-6 on nerve cells.
Nerve growth factor (NGF) was shown to induce a pheno-
typic shift in chromaffin cells and their neoplastic counter-
part, PC12 cell line, resulting in neural differentiation
accompanied by chemical, ultrastructural, and morphologi-
cal changes. IL-6 was also found to induce the typical
differentiation of PCi 2 cells into neural cells.62 In fact, in the
presence of IL-6, the cell viability was maintained and a
change in morphology to neurite-extending cells was
observed after several days. Furthermore, IL-6 was found to
induce the transient expression of c-fos proto-oncogene and
an increase in the number of voltage-dependent Na￿ chan-
nels in PC 12 cells. The differentiation induced by IL-6 is
similar to that observed with NGF, although IL-6 and NGF
use completely different receptors on PC i 2 cells, Moreover,
it was found that PC12 cells express about 1,200 IL-6
receptors per cell with a Kd value of -i.8 x iO￿ mol/L.
IL-6 could show its effect on hypothalamo-pituitary-
adrenal axis in vivo. Intravenous (IV) administration of IL-6
into rats increased the plasma level of adrenocorticotropic
hormone 30 minutes after the injection.63 The injection of
anticorticotropin-releasing hormone ten minutes before IL-6
completely abolished the IL-6-induced increase of ACTH,
suggesting that IL-6 stimulated the secretion of ACTH
through the cortiocotropin-releasing hormone. IL-6 showed a
synergistic effect with glucocorticoid on the induction of
acute phase proteins.59 Thus, IL-6-induced secretion of
ACTH may have a positive feed back loop on acute phase
reaction. On the other hand, glucocorticoid is a potent
inhibitor in the induction of IL-6 production in various cells.
Therefore, the interaction of IL-6 with neuro-endocrine
system may regulate positively and negatively acute phase
reactions and immune responses.
IL-6 was found to be produced in a murine CNS by
infection with lymphocytic choriomeningitis virus or with
vesicular stomatitis virus.35 Both virus-infected microglial
cells and astrocytes produced IL￿6.M The production of IL-6
may explain the mechanisms leading to the intrathecal
antibody production by B cells having infiltrated the brain
tissue. It was also found that IL-6 induced an increase in the
secretion of a neurotrophic factor, nerve growth factor by
astrocytes. Thus, IL-6 production may be involved in repair
mechanism besides antibody production in the course of viral
infection.
RECEPTORS AND SIGNAL TRANSDUCTION
IL-6 provides multiple signals on various tissues and cells.
As summarized in Table 3, these signals can be divided into
three categories: (a) induction of differentiation or specific
gene expression such as Ig induction in B cells or the
induction of acute phase proteins in hepatocytes; (b) stimula-
tion of cell growth, such as the induction of myeloma/
plasmacytoma growth or T cell growth; and (c) inhibition of
cell growth, such as inhibition of growth of myeloid leukemia
cells or breast cancer cells. In order to know the mechanism
how a single cytokine can provide multiple signals, the
molecular structure of the specific receptor should be
revealed.
The number of cytokine receptors is usually in the order of
102 to iO￿, which is 100-fold less than that for hormone or
growth factor receptors. The IL-6 receptor is not exceptional
as shown in Table 4. As expected from its pleiotropic
function, receptors are expressed on various cells, such as
activated B cells, resting T cells, B lymphoblastoid cell lines,
myeloma cell lines, hepatoma lines, and monocyte cell lines.
The number of the receptors is between 102 and iO￿ and a
myeloma cell line, U266, expresses the maximum number of
receptors, approximately 1 to 2 x iO￿, which may fit for the
activity of IL-6 as myeloma growth factor.39
cDNA for IL-6 receptor has been cloned by using high
Table 3. Multiple Signals Provided by 11-6
Induction of differentiation or specific gene expression
Ig-induction in B cells
Induction of acute phase proteins in liver cells
Induction of cytotoxic T-ceII differentiation
Induction of neural cell (PC 12) differentiation
Activation of hematopoietic stem cells from G,,, to G,
Stimulation of cell growth
Induction of the growth of myeloma/plasmacytoma cells
Induction of T cell growth
Induction of mesangial cell growth
Inhibition of cell growth
Growth inhibition of myeloid leukemia cells (M 1 cells)
Growth inhibition of breast carcinoma cell lines
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Table 4. 11-6 Receptor Expres sed on Various Cells
Cells No. of Receptor/Cell
Activated B cells
Resting B cells
Resting T cells
EBV-transformed B-cell lines
Burkitt’s lymphoma lines
Myeloma cells and cell lines
Hepatoma cell lines
Myeloid leukemia cell lines
Rat pheochromocytoma (PC 12)
-500
Nondetectable
-‘300
200-3,000
Nondetectable
100-20,000
2,000-3,000
2.000---3,000
-‘ 1,000
efficiency COS cell expression vector.65 As shown in Fig 5,
the receptor consists of 468 amino acids with a single
transmembrane segment. The intracytoplasmic portion con-
sists of 82 amino acids and it does not have a tyrosine kinase
domain, although IL-6 is a potent growth factor for myeloma
cells. Comparison of the sequence shows that IL-6 receptor
belongs to the C2 set of the Ig superfamily and first hundred
amino acids formed an Ig-like domain. Noteworthy is that all
the receptors for cytokines so far cloned, PDGF,￿ CSF- 1 67
IL-I,￿ and IL-66’ belong to the C2 set ofthe Ig superfamily.
IL-6 receptor has five possible N-glycosilation sites and the
molecular weight (mol wt) of mature protein is 80 Kd.
Crosslinking experiments with ‘251-IL-6 showed that only a
single polypeptide chain with 80 Kd mol wt is involved in the
binding with IL-6. However, the binding of IL-6 with the 80
Kd IL-6 receptor triggers the association of the second
nonligand binding polypeptide chain with 130 Kd mol wt
(Taga et al, submitted). The mutated IL-6 receptor without
intracytoplasmic portion could transmit the IL-6 signal,
indicating that the second nonligand binding chain is respon-
sible for the signal transduction. Therefore, IL-6 receptor
consists of two polypeptide chains, a ligand-binding chain
and a nonligand binding, signal transducing chain, the
results suggest a novel mechanism for the signal transduc-
tion. Physicochemical properties of IL-6 and its receptor are
summarized in Table 5.
IL-6 AND DISEASES
Multilpie myelomas/plasmacytomas. As described, IL-
6 is a potent growth factor for myeloma/plasmacytoma cells,
suggesting a possible involvement of IL-6 in the generation of
myeloma/plasmacytoma. The study with myeloma cells
freshly isolated from the bone marrow of myeloma patients
demonstrated that IL-6 is an autocrine growth factor for
human myeloma cells.69 In fact, (a) IL-6 augments the in
vitro growth of myeloma cells, (b) myeloma cells produce
IL-6, and (c) anti-IL-6 inhibits the spontaneous growth of
myeloma cells. In 26 cases of myelomas tested, 12 cases that
were at the early clinical stage were responsive to IL-6 for
their growth, but myeloma cells derived at late clincal stages
were refractory to IL-6 stimulation.7#{176} These results suggest
that IL-6 is an essential autocrine growth factor for myeloma
cells and its dyregulated expression may be involved in the
oncogenesis of human multiple myelomas.
This was further confirmed by transgenic mice carrying
the human IL-6 gene conjugated with the Ig enhancer
(E￿z-IL-6). The transgenic mice showed the generation of
plasmacytomas (Suematsu et al, submitted for publication).
However, these plasmacytoma cells were polyclonal and not
transplantable. Furthermore, they did not show the c-myc
translocation. Therefore, the result suggests that constitutive
expression of IL-6 in B lineage cells induces polyclonal
proliferation of IL-6 dependent plasmacytomas and a second
event such as c-myc translocation during continuous prolifer-
ation may transform cells into monoclonal and transplant-
able plasmacytomas.
In 1962, Potter and Boyce demonstrated the induction of
plasmacytomas in BALB/c mice by intraperitoneal injection
of mineral oil.7’ Plasmacytomas were generated exclusively
in oil-induced granulomatous tissues that produced a large
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Table 5. Physicochemical Pr operties of Human 11-6 and IL-6R
IL-S lL-6R
Apparent molecular weight (Kd) 2 1 80
Number of amino acids
Total 212 468
Matureprotein 184 449
N-glycosylation sites 2 5
Transmembrane segment Single
Intracytoplasmic portion 82 amino acid
Sequence homology G-CSF Ig superfamily
No tyrosine
kinase domain
Genomic structure 5 exons Not known
Chromosomal location Chromosome 5 Not known
amount of plasmacytoma growth factor. As described, plas-
macytoma growth factor was molecularly cloned and shown
to be a murine homologue of IL-6.22’23 Therefore, the study
performed by Potter and Boyce as well as the observations
made in the transgenic mice with the E￿-IL-6 gene indicate
an essential role of IL-6 in the oncogenesis of murine
plasmacytomas.
Castleman’s disease. In 1956, Castleman et al reported
a group of patients with a large, benign hyperplastic medias-
tinal lymph node that resembled thymomas.72 Since then, a
syndrome consisting of fever, anemia, hyper ￿y-globulinemia
and increase in acute phase proteins in association of consis-
tent benign hyperplastic lymph nodes has been called Castle-
man’s disease. The affected lymph nodes are characterized
by massive infiltration of plasma cells. Sometimes, patients
develop monoclonal gammapathy and finally multiple
myelomas. Of particular interest is that the above mentioned
clinical abnormalities disappear after excision of the affected
lymph node. The germinal center of hyperplastic lymph
nodes of patients with Castleman’s disease were found to
produce constitutively large quantities of IL-6 with no signif-
icant production of other cytokines (Yoshizaki et al, submit-
ted). Dramatic clinical improvement and decrease in serum
IL-6 were observed following surgical removal of the
involved lymph node. Considering the multiple biological
activities of IL-6, the aberrant constitutive expression of IL-6
by the germinal center B cells in the affected lymph nodes
can explain the symptoms of this rare disease and the
abnormal regulation of IL-6 expression may be the primary
event in the pathogenesis of Castleman’s disease.
Lennert’s T-cell lymphoma. IL-6 was shown to be
involved in the in vitro as well as in vivo growth of Lennert’s
T lymphoma cells.73 Lennert’s lymphoma is a special variant
of non-Hodgkin’s lymphoma characterized by a massive
infiltration of macrophage-derived epithelioid histiocytes. A
T lymphoma cell line established from a patient with Len-
nert’s lymphoma showed macrophage-dependent growth and
the function of macrophages could be replaced with macro-
phage-derived soluble factor(s). IL-6 supported the in vitro
growth of such an established T-cell line and anti-IL-6
antibody could completely neutralize the activity of macro-
phage-derived factor. Considering the massive infiltration of
macrophges in lymphoma tissues, the evidence suggests that
macrophage-derived IL-6 may be involved in the in vivo
growth of Lennert’s lymphoma.
Polyclonal B-cell activation and autoimmune dis-
eases. Cardiac myxoma is a benign intraatrial heart tumor
and interestingly patients often show autoimmune symptoms
and autoantibody production, which disappear after surgical
removal of myxoma cell.74 Study with cardiac myxoma cells
demonstrated that they constitutively produced large
amounts of IL-6.75 Several other cancers also aberrantly
produced IL-6 and patients showed autoantibody produc-
tion. The results suggest that abnormal production of IL-6 in
vivo may induce polyclonal B cell activation and autoanti-
body production.
These observations suggest that abnormal expression of
IL-6 may contribute to the generalized autoimmune disease,
such as rheumatoid arthritis. In fact, high levels of IL-6 were
detected in synovial fluid from the joints of patients with
active RA.76 The synovial cells as well as the infiltrated T and
B cells constitutively produced IL-6. The overproduction of
IL-6 can explain the local as well as the generalized symp-
toms of RA, such as infiltration of plasma cells into synovial
tissues, autoantibody production and elevation of acute phase
proteins including CRP and serum amyloid A. IL-6 was
found to be a growth factor for EBV-transformed B lympho-
blastoid cells. This may explain the presence of abnormally
elevated numbers of circulating EBV-infected B cells in RA
patients. Diseases related to the abnormal expression of IL-6
are summarized in Table 6.
SUMMARY AND FUTURE PROSPECTS
Most cytokines involved in the regulation of the immune
responses and hematopoiesis have been molecularly cloned.
The studies with recombinant molecules clearly demonstrate
that the function of these cytokines is not specific to a certain
lineage of cells as originally expected but they show a wide
variety of biological functions on various tissues and cells.
One of the most typical examples of these multifunctional
cytokines is IL-6. As described, it regulates immune
responses, hematopoiesis, and acute phase reactions, indicat-
ing that it plays a central role in host defense mechanism.
Among many cytokines, IL-6 is the first one, the abnormal
expression of which is directly related to the pathogenesis of
several diseases, such as myeloma/plasmacytoma, Castle-
man’s disease, and mesangium proliferative glomerulone-
phritis, in which IL-6 functions as an autocrine growth factor
for kidney mesangium cells. Therefore, the study on the
regulatory mechanism of the IL-6 gene expression is indis-
pensable for unraveling the molecular pathogenesis of those
diseases. Neutralization of IL-6 with specific inhibitors may
be applied for the treatment of such diseases. Soluble recep-
tors are possible candidates as the specific inhibitor.
The signal transduction through cytokine receptors may
be unique: (a) the number of receptors is approximately
Table 6. Deregulation of 11-6 Expression and Diseases
Myelomas and plasmacytomas
Castleman’s disease
Rheumatoid arthritis
Mesangial proliferative glomerulonephritis
Cardiac myxoma
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100-fold less than that of hormone or growth factor receptors
and (b) any known biochemical reactions, such as phosphati-
dyl inositol turnover, tyrosine phosphorylation, and Ca￿ k-ion
influx, are not invoked following stimulation with cytokines.
Recently, cDNAs for cytokine receptors, such as IL-6, IL-i
and “y-IFN have been cloned. The receptor molecules do not
have any unique structure for the signal transduction, such as
tyrosine kinase domain. Therefore, the presence of associated
molecules for the signal transduction is assumed. In fact,
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